153 related articles for article (PubMed ID: 17962725)
1. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
2. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
[TBL] [Abstract][Full Text] [Related]
3. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
McCluggage WG; Strand K; Abdulkadir A
Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths.
Alshenawy HA
Ann Diagn Pathol; 2010 Dec; 14(6):387-95. PubMed ID: 21074685
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression.
Sillanpää SM; Anttila MA; Voutilainen KA; Ropponen KM; Sironen RK; Saarikoski SV; Kosma VM
Int J Cancer; 2006 Oct; 119(8):1792-9. PubMed ID: 16804904
[TBL] [Abstract][Full Text] [Related]
8. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
[TBL] [Abstract][Full Text] [Related]
10. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of extracellular matrix metalloproteinase inducer is associated with matrix metalloproteinase-1 and -2 in gingival tissues from patients with periodontitis.
Dong W; Xiang J; Li C; Cao Z; Huang Z
J Periodontal Res; 2009 Feb; 44(1):125-32. PubMed ID: 19515022
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
13. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
14. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
[TBL] [Abstract][Full Text] [Related]
15. Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Yao CW; Loh SH; Cheng MF; Hsieh DS; Bai CY
Int J Gynecol Pathol; 2006 Apr; 25(2):140-6. PubMed ID: 16633062
[TBL] [Abstract][Full Text] [Related]
16. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
[TBL] [Abstract][Full Text] [Related]
18. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
19. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
20. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
Noske A
Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]